Seagen Inc. Insider Trading for August 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Seagen Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Seagen Inc. for August 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 47.89 | 4,937 | 236,455 | 228,015 | 233 K to 228 K (-2.12 %) |
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 47.89 | 25,506 | 1,221,597 | 678,129 | 703.6 K to 678.1 K (-3.62 %) |
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Sell | S | 47.89 | 6,377 | 305,423 | 164,906 | 171.3 K to 164.9 K (-3.72 %) |
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | DRACHMAN JONATHAN G | CMO & EVP, R & D | Sell | S | 47.89 | 8,502 | 407,199 | 133,702 | 142.2 K to 133.7 K (-5.98 %) |
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 47.89 | 5,343 | 255,900 | 117,424 | 122.8 K to 117.4 K (-4.35 %) |
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 47.89 | 1,788 | 85,635 | 76,868 | 78.7 K to 76.9 K (-2.27 %) |
| Aug 25 2017 | SGEN | SEATTLE GENETICS I ... | DRACHMAN JONATHAN G | CMO & EVP, R & D | Option Exercise | M | 10.29 | 10,000 | 102,900 | 0 | |
| Aug 25 2017 | SGEN | SEATTLE GENETICS I ... | DRACHMAN JONATHAN G | CMO & EVP, R & D | Sell | S | 47.54 | 10,000 | 475,414 | 142,204 | 152.2 K to 142.2 K (-6.57 %) |
| Aug 25 2017 | SGEN | SEATTLE GENETICS I ... | DRACHMAN JONATHAN G | CMO & EVP, R & D | Buy | M | 10.29 | 10,000 | 102,900 | 152,204 | 142.2 K to 152.2 K (+7.03 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 46.37 | 55,344 | 2,566,301 | 55,344 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 23,000 | 0 | 232,952 | 210 K to 233 K (+10.95 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | A | 46.37 | 165,844 | 7,690,186 | 165,844 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Grant | A | 0.00 | 67,200 | 0 | 703,635 | 636.4 K to 703.6 K (+10.56 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Leg Affairs | Option Exercise | A | 46.37 | 40,344 | 1,870,751 | 40,344 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Leg Affairs | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | LIU JEAN I | GC/EVP, Leg Affairs | Grant | A | 0.00 | 17,000 | 0 | 68,400 | 51.4 K to 68.4 K (+33.07 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Option Exercise | A | 46.37 | 47,844 | 2,218,526 | 47,844 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | HIMES VAUGHN B | Chief Technical Off ... | Grant | A | 0.00 | 20,000 | 0 | 171,283 | 151.3 K to 171.3 K (+13.22 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DRACHMAN JONATHAN G | CMO & EVP, R & D | Option Exercise | A | 46.37 | 65,344 | 3,030,001 | 65,344 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DRACHMAN JONATHAN G | CMO & EVP, R & D | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DRACHMAN JONATHAN G | CMO & EVP, R & D | Grant | A | 0.00 | 27,000 | 0 | 142,204 | 115.2 K to 142.2 K (+23.44 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 46.37 | 85,344 | 3,957,401 | 85,344 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Grant | A | 0.00 | 35,000 | 0 | 122,767 | 87.8 K to 122.8 K (+39.88 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | A | 46.37 | 40,344 | 1,870,751 | 40,344 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Grant | A | 0.00 | 17,000 | 0 | 78,656 | 61.7 K to 78.7 K (+27.57 %) |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Option Exercise | M | 10.29 | 10,413 | 107,150 | 0 | |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Sell | S | 48.91 | 10,413 | 509,300 | 636,435 | 646.8 K to 636.4 K (-1.61 %) |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | SIEGALL CLAY B | President and CEO | Buy | M | 10.29 | 10,413 | 107,150 | 646,848 | 636.4 K to 646.8 K (+1.64 %) |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Option Exercise | M | 18.46 | 6,000 | 110,760 | 2,907 | |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Sell | S | 49.19 | 6,000 | 295,110 | 61,656 | 67.7 K to 61.7 K (-8.87 %) |
| Aug 09 2017 | SGEN | SEATTLE GENETICS I ... | Cline Darren S | EVP, Commercial | Buy | M | 18.46 | 6,000 | 110,760 | 67,656 | 61.7 K to 67.7 K (+9.73 %) |